Retreatment with trastuzumab after relapse following adjuvant trastuzumab treatment (the RHEA trial): preliminary efficacy data

被引：2

作者：

Belli, R. ^{[1
]}

Feng-Yi, F. ^{[2
]}

Barrios, C. H. ^{[3
]}

Yu, S. Y.

Lopez, R. I. ^{[5
]}

Khasanov, R. ^{[4
,6
]}

Semigiazov, V. ^{[7
]}

Feyereislova, A. ^{[8
]}

Muehlbauer, S. ^{[8
]}

Jassem, J. ^{[9
]}

机构：

[1] Geelong Hosp, Andrew Love Canc Ctr, Geelong, Vic, Australia

[2] Chinese Acad Med Sci, Canc Inst Hosp, Beijing, Peoples R China

[3] Pontificia Univ Catolica Rio Grande do Sul, Hosp Sao Lucas, Serv Oncol, Porto Alegre, RS, Brazil

[4] Tongji Med Univ, Dept Oncol, Wuhan, Peoples R China

[5] Natl Oncol Inst, Panama City, Panama

[6] Tatarstan Republ Oncol Hosp, Kazan, Russia

[7] NN Petrov Oncol Res Inst, St Petersburg, Russia

[8] F Hoffmann La Roche & Co Ltd, Basel, Switzerland

[9] Med Acad, Gdansk, Poland

来源：

EJC SUPPLEMENTS | 2007年 / 5卷 / 04期

关键词：

D O I：

10.1016/S1359-6349(07)70882-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2120

引用

页码：220 / 220

页数：1